G Wolbink
Overview
Explore the profile of G Wolbink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nassar-Sheikh Rashid A, Schonenberg-Meinema D, Bergkamp S, Bakhlakh S, De Vries A, Rispens T, et al.
Pediatr Rheumatol Online J
. 2021 Apr;
19(1):59.
PMID: 33926495
Background: Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. However, evidence for individual treatment decisions based on serum anti-TNF drug levels and the...
2.
Vogelzang E, Hebing R, Nurmohamed M, van Kuijk A, Kruijff J, Lami M, et al.
PLoS One
. 2018 Oct;
13(10):e0205125.
PMID: 30300358
Objectives: To determine the percentage non-adherence to etanercept in patients with rheumatoid arthritis during three years of follow-up. Methods: During study visits in this prospective cohort study, blood samples were...
3.
van Vollenhoven R, Lami M, Wolbink G
Tijdschr Psychiatr
. 2018 Mar;
60(3):146-150.
PMID: 29521400
Background: An important goal in medicine is to provide patients with individualised and personalised treatment. Personalised medicine is making an important contribution. Aim: To summarise developments in the field of...
4.
Ruwaard J, Lami M, Marsman A, Kneepkens E, van Denderen J, van der Horst-Bruinsma I, et al.
Scand J Rheumatol
. 2017 Jul;
47(2):122-126.
PMID: 28745108
Objective: To compare rates of drug survival and clinical response during 2 years of follow-up in ankylosing spondylitis (AS) patients treated with etanercept or adalimumab in routine care. Method: Biological-naïve...
5.
Kneepkens E, Van Den Oever I, Plasencia C, Pascual-Salcedo D, De Vries A, Hart M, et al.
Scand J Rheumatol
. 2016 Jul;
46(2):87-94.
PMID: 27440258
Objectives: To investigate the pharmacokinetics (PK) and dynamics of tocilizumab (TCZ) in daily practice. Method: An observational study of 66 consecutive RA patients treated with TCZ 8 mg/kg once every...
6.
Marsman A, Kneepkens E, Ruwaard J, Wei J, Nurmohamed M, van Denderen C, et al.
Scand J Rheumatol
. 2016 Jan;
45(4):331-4.
PMID: 26727457
No abstract available.
7.
Suurmond J, Rivellese F, Dorjee A, Bakker A, Rombouts Y, Rispens T, et al.
Ann Rheum Dis
. 2014 May;
74(10):1915-23.
PMID: 24818634
Objective: Mast cells may play a role in rheumatoid arthritis (RA), but activation of human mast cells in autoimmune settings has been little studied. Toll-like receptors (TLR) and Fcγ receptors...
8.
Krieckaert C, Nair S, Nurmohamed M, van Dongen C, Lems W, Lafeber F, et al.
Ann Rheum Dis
. 2013 Nov;
74(2):361-8.
PMID: 24265411
Objective: To evaluate the cost-effectiveness of personalised treatment for rheumatoid arthritis (RA) using clinical response and serum adalimumab levels. Methods: A personalised treatment algorithm defined, based on clinical (European League...
9.
van Kuijk A, Gerlag D, Vos K, Wolbink G, de Groot M, de Rie M, et al.
Ann Rheum Dis
. 2008 Jul;
68(8):1303-9.
PMID: 18647851
Objective: To determine which of the changes in synovial tissue correlates best with clinical response associated with effective therapy (adalimumab) to facilitate the planning of future studies with therapeutic agents...
10.
van der Laken C, Voskuyl A, Roos J, Stigter van Walsum M, de Groot E, Wolbink G, et al.
Ann Rheum Dis
. 2006 Jun;
66(2):253-6.
PMID: 16793840
Background: Many patients with rheumatoid arthritis are currently successfully treated with infliximab (anti-tumour necrosis factor); however, about 30% of the patients do not respond to infliximab. One of the postulated...